HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio

Size: px
Start display at page:

Download "HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio"

Transcription

1 HBM Healthcare Investments Ltd Access to a Global and Diversified Private Equity Healthcare Portfolio SECA conference Zurich, 3 July 2013 Dr. Andreas Wicki, CEO

2 HBM at a Glance SIX-listed investment company (Ticker: HBMN SW Equity) Net assets (NAV) Market capitalisation CHF 670 million CHF 543 million NAV per share CHF Share price CHF Discount 23.1% Number of issued shares Number of shareholders million Performance Share price since 1 Jan 13 (YTD) +27.2% % NAV since 1 Jan 13 (YTD) +30.4% % Charts as at 31 May 2013 (since first listing on SIX Swiss Exchange on 14 Feb 2008); indexed ( = 100) CHF USD HBM NAV page 2 HBM Share price MSCI World Health Care Index HBM NAV HBM Share price MSCI World Health Care Index

3 A Global Healthcare Portfolio page 3 ChemoCentryx Intervent. Spine Ellipse Tensys Pacira Enanta PTC Ophthotech SkyePharma Basilea Swedish Orphan Probiodrug Nabriva Medimpulse Cathay Private companies Public companies 15 largest direct investments

4 Largest Investments (1/2) Company Main business Infectious diseases (Antiinfectives) Phase of Lead Product Ticker Market Capitalisation (CHF m) Ownership in % Book value (CHF m) page 4 In % of NAV Phase III BSLN 688 < ,1 22,2 Injectable medicines with (patented) controlled release of active drug Back-of-the-eye diseases, focusing on macular degeneration (AMD) Long chain diacids, carbohydrates and special enzymes Infectious diseases (Hepatitis C) Autoimmune diseases, inflammatory disorders and cancer Market PCRX 923 6,5 59,8 8,9 Phase III Private 298 1) 13,5 40,3 6,0 Markt Private 212 1) 12,6 26,7 4,0 Phase III ENTA 332 7,8 26,0 3,9 Phase III CCXI 540 4,4 24,3 3,6 As at 31 May 2013 (FX USD/CHF: , FX EUR/CHF: ) 1) For private companies: Implied company valuation

5 Largest Investments (2/2) Company Main business Phase of Lead Product Ticker Market Capitalisation (CHF m) Ownership in % Book value (CHF m) page 5 In % of NAV Genetic diseases Phase III Private 172 1) 12,3 21,1 3,1 Serious skin infections and bacterial pneumonia Phase II Private 136 1) 11,9 16,2 2,4 Minimally invasive spinal implants Drug delivery for oral and inhalation products Market Private 52 1) 31,4 16,2 2,4 Market SKP 34 23,8 16,2 2) 2,4 Hemodynamic patient monitoring Market Private 10 1) 100,0 9,9 1,5 Products for treatment of rare diseases Market SOBI ,5 8,3 1,2 As at 31 May 2013 (FX USD/CHF: , FX EUR/CHF: ) 1) For private companies: Implied company valuation 2) Shares and Bond

6 Pacira Pharmaceuticals The EXPAREL Growth Story page 6 Share price since IPO on 3 Feb 2011 (in USD) Quarterly sales of Exparel (in million USD) x 4.2 Data as at 31 May 2013 Market cap USD 967m Enterprise value USD 953m Book value HBM USD 63m Ownership 6.5% Analyst consensus estimates for annual sales Multiple on invested capital of 2.7x

7 Pacira Pharmaceuticals HBM is an Active long-term Shareholder First investment of HBM in syndicate with MPM Capital, OrbiMed Advisors LLC and Sanderling Ventures Strengthening of management team and board representation March 07 Established as spin-out of the Skye Pharma Injectable Business Further investments Oct / Dec 09 Phase III studies reached primary endpoint Actively involved in strategic discussions, business development and IPO preparation Dec 10 NDA acceptance by the FDA Further investments at IPO and follow-on Feb 11 IPO on the NASDAQ Okt. 11 EXPAREL received US market approval from the FDA for the treatment of post-operative pain April 12 - Commercial rollout of EXPAREL in the US; reported clinical data suggests label expansion into other high growing sectors page 7

8 Why Invest in HBM Healthcare Investments? page 8 Invested in emerging therapies: Orphan and infectious diseases, Hep C and wet AMD Near-term value inflection points Balanced and diversified portfolio of de-risked late stage assets and growth companies both private and public Long-term expertise of investing in private and public companies Actively managed investment positions Committed to Shareholders Share buy-back and cash distribution

9 Contact page 9 HBM Healthcare Investments Ltd Bundesplatz 1 CH-6300 Zug Switzerland Phone Fax

10 Disclaimer page 10 Cautionary Statement This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of HBM Healthcare Investments Ltd, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of HBM Healthcare Investments Ltd, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. HBM Healthcare Investments Ltd disclaims any obligation to update these forward-looking statements to reflect future events or developments.

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA

NOT FOR DISTRIBUTION IN THE USA,CANADA, JAPAN OR AUSTRALIA Press release Baar, 28 January 2008 Attractive portfolio of investments in biotech and medical technology to be opened to the public HBM BioVentures announces further information of its planned IPO on

More information

For personal use only

For personal use only 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS) Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor

More information

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile The Business

More information

KOHLBERG CAPITAL CORPORATION. May 2007

KOHLBERG CAPITAL CORPORATION. May 2007 KOHLBERG CAPITAL CORPORATION May 2007 Safe Harbor Statement Private Securities Litigation Reform Act of 1995 Forward Looking Information This presentation may include forward-looking statements. These

More information

Omeros Raises More Than $63 Million in Financing

Omeros Raises More Than $63 Million in Financing Omeros Raises More Than $63 Million in Financing Seattle, WA February 12, 2007 Omeros today announced that it has raised in excess of $63 million in an oversubscribed Series E equity financing. New investors,

More information

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Acadia Pharmaceuticals Inc. (ACAD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Karo Pharma AB (KARO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Rationale for the proposed transaction

Rationale for the proposed transaction PRESS RELEASE Fortis Healthcare Limited Board of Directors approves demerger of its diagnostics business into a separate listed Company through a composite scheme of arrangement Gurgaon, August 19, 2016

More information

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner

Global Source Ventures, LLC Introduction. Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Global Source Ventures, LLC Introduction Antonius Schuh Managing Partner Stephen Zaniboni Managing Partner Introduction to Global Source Ventures GSV provides seed capital to emerging companies with emphasis

More information

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Natera, Inc. (NTRA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile Emcure Pharmaceuticals Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile ConvaTec Group Plc - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

State of Licensing 2011 Update

State of Licensing 2011 Update State of Licensing 2011 Update Moderators/Speakers Hemmie Chang, Chair, Licensing & Strategic Alliance Practice Group, Foley Hoag LLP Ranya Dajani, Executive Director, Strategic Transactions Group, Bristol-

More information

ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital

ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital August 14, 2017 ianthus Announces Proposed Acquisition of Citiva Medical and Citiva USA and Termination of Proposed Transaction with Gloucester Street Capital To Acquire One of Ten License Holders in New

More information

INVESTOR PRESENTATION!

INVESTOR PRESENTATION! INVESTOR PRESENTATION ENHANCING HEALTH THROUGH CANNABIS SCIENCE WWW.EMERALDHEALTH.CA TSX.V:EMH TSX.V:EMH Disclaimer THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING

More information

CeQur establishes Wales subsidiary

CeQur establishes Wales subsidiary FOR IMMEDIATE RELEASE CeQur establishes Wales subsidiary -- Arthurian Life Sciences investment helps bring to market world s first three-day simple insulin infusion device for type 2 diabetes -- LUCERNE,

More information

Management to Host Conference Call at 8:30 a.m. ET today

Management to Host Conference Call at 8:30 a.m. ET today Aclaris Therapeutics Reports Second Quarter 2016 Financial Results August 11, 2016 7:01 AM ET Management to Host Conference Call at 8:30 a.m. ET today MALVERN, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:ACRS),

More information

HBM Healthcare Investments Ltd

HBM Healthcare Investments Ltd HBM Healthcare Investments Ltd Access to a Global and Diversified Healthcare Portfolio February 2019 HBM Healthcare Investments Ltd About HBM Healthcare Investments Ltd Investment Strategy Healthcare Sector

More information

NASDAQ: CASI Partnering Presentation

NASDAQ: CASI Partnering Presentation NASDAQ: CASI Partnering Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to

More information

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile

Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile Starpharma Holdings Limited (SPL) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

VentureSource Europe -- 3Q 2014

VentureSource Europe -- 3Q 2014 Europe -- 3Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, and liquidity. The included charts and graphs offer a

More information

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing

More information

HBM Healthcare Investments Ltd

HBM Healthcare Investments Ltd HBM Healthcare Investments Ltd Access to a Global and Diversified Healthcare Portfolio January 2019 HBM Healthcare Investments Ltd About HBM Healthcare Investments Ltd Investment Strategy Healthcare Sector

More information

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bioton SA (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and market

More information

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018

KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 KKR & Co. L.P. Morgan Stanley Financials Conference: June 13, 2018 ($ in trillions) KKR Growth in Alternative Asset Market Share KKR AUM +20% CAGR +21% CAGR Alternative AUM +12% CAGR $190 (1) ($ in billions)

More information

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Pharmaxis Ltd (PXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Page 1 of 5 LEGAL_1:

Page 1 of 5 LEGAL_1: Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018 Patient enrollment in the two TRILOGY Phase 3 studies is progressing as planned: 463 patients enrolled and 41 patients randomized at

More information

Sony IR Day Game & Network Services Segment. November 25, Andrew House

Sony IR Day Game & Network Services Segment. November 25, Andrew House Sony IR Day 2014 November 25, 2014 Andrew House President and Group CEO Sony Computer Entertainment Inc. Group Executive in Charge of Network Entertainment Business Sony Corporation Agenda 1. Business

More information

An Australian Company with Growing Onshore Oil Production in Indonesia

An Australian Company with Growing Onshore Oil Production in Indonesia ASX:BAS www.bassoil.com.au An Australian Company with Growing Onshore Oil Production in Indonesia Noosa Mining & Exploration Investor Conference 18 July 2018 Forward Looking Statements This presentation

More information

HBM Healthcare Investments Ltd

HBM Healthcare Investments Ltd HBM Healthcare Investments Ltd Access to a Global and Diversified Healthcare Portfolio November 2018 HBM Healthcare Investments Ltd About HBM Healthcare Investments Ltd Investment Strategy Healthcare Sector

More information

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved.

Dealdoc. Acquisition agreement for Gambro. Baxter International Gambro. Dec , Wildwood Ventures Ltd. All rights reserved. Dealdoc Acquisition agreement for Gambro Baxter International Gambro Dec 04 2012 Acquisition agreement for Gambro Companies: Baxter International Gambro Announcement date: Dec 04 2012 Deal value, US$m:

More information

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile DaVita HealthCare Partners Inc. (DVA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sector

More information

Cherry AB. The most complete gaming company Partnering with entrepreneurs to explore exciting ideas

Cherry AB. The most complete gaming company Partnering with entrepreneurs to explore exciting ideas Cherry AB The most complete gaming company Partnering with entrepreneurs to explore exciting ideas CEO Anders Holmgren & CFO Christine Rankin Copenhagen 10 January 2018 Investment case Positive outlook

More information

Wood Group Investor Briefing Q1 2016

Wood Group Investor Briefing Q1 2016 Wood Group Investor Briefing Q1 2016 Our business Wood Group is an international projects, production and specialist technical solutions provider with around $6bn sales and 36,000 employees. We are focused

More information

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS

PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS PRESS RELEASE FOR IMMEDIATE RELEASE PROMETIC REPORTS 2017 THIRD QUARTER HIGHLIGHTS AND FINANCIAL RESULTS US $80 million (CAD $100 million) line of credit secured from Structured Alpha LP Plasminogen BLA

More information

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio

August 17, The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Joint Democratic and Republican House Policy Committee Hearing August 17, 2016 The Testimony of Christopher P. Molineaux President & CEO Pennsylvania Bio Chairman Benninghoff, Chairman Sturla, and members

More information

HBM Healthcare Investments Ltd

HBM Healthcare Investments Ltd HBM Healthcare Investments Ltd Access to a Global and Diversified Healthcare Portfolio September 2018 HBM Healthcare Investments Ltd About HBM Healthcare Investments Ltd Investment Strategy Healthcare

More information

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Becton, Dickinson and Company (BDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio

More information

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018

KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR & Co. Inc. Goldman Sachs U.S. Financial Services Conference December 4, 2018 KKR Today Private Markets Public Markets Capital Markets Principal Activities $104bn AUM $91bn AUM Global Franchise $19bn

More information

COMET EXPLORATION Chilean Copper. October 2018

COMET EXPLORATION Chilean Copper. October 2018 COMET EXPLORATION Chilean Copper October 2018 C O N T E Proven Team Excellent Portfolio/ Location Wholly owned assets Capital Picture N T Peer Comparisons Investment highlights Timeline to listing / Pre

More information

PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS. Announces Name Change to Walker Innovation Inc.

PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS. Announces Name Change to Walker Innovation Inc. PATENT PROPERTIES ANNOUNCES SECOND QUARTER 2015 RESULTS Announces Name Change to Walker Innovation Inc. Announces Name Change of its United States Patent Utility Service to Haystack IQ Trial Usage of New

More information

Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans - Acquisitions, Financing, Expansion Initiatives & Strategic Plans MIRAMAR, FL, January 22, 2019 - Generex Biotechnology Corporation (www.generex.com)

More information

Cherry AB. Investing in a broad gaming portfolio. CEO Anders Holmgren GP Bullhound 6 December 2017

Cherry AB. Investing in a broad gaming portfolio. CEO Anders Holmgren GP Bullhound 6 December 2017 Cherry AB Investing in a broad gaming portfolio CEO Anders Holmgren GP Bullhound 6 December 2017 The game is on Cherry is investing in a broad portfolio of online gaming companies Cherry s strategy is

More information

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. CASI Pharmaceuticals, Inc. Your Strategic Drug Development Partner in China NASDAQ: CASI WWW.CASIPHARMACEUTIALS.COM Forward Looking Statements This presentation contains forward-looking statements within

More information

HBM Healthcare Investments Ltd

HBM Healthcare Investments Ltd HBM Healthcare Investments Ltd Access to a Global and Diversified Healthcare Portfolio July 2018 HBM Healthcare Investments Ltd About HBM Healthcare Investments Ltd Investment Strategy Healthcare Sector

More information

ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People

ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People February 1, 2018 ianthus Closes Acquisition of Citiva Medical and Citiva USA, Gaining Access to New York's Population of Approximately 20 Million People Company to Host a Conference Call at 9:00am ET on

More information

Biotech Concerto #6 Investment Process December 2008

Biotech Concerto #6 Investment Process December 2008 Biotech Concerto #6 Investment Process December 2008 Index Biotech Investment Characteristics Investment Policy Investment Team Scientific Advisory Board Deal Flow Attrition Rate From Screening to Decision

More information

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview

WOLPERT ASSOCIATES, INC. Strategic Advisory Services Firm Overview Strategic Advisory Services 2018 Firm Overview Our Foundational Principles Strategic Advice for Biopharmaceutical, Medical Technology and Life Science sectors A Focus on Strategic Thinking in the Context

More information

Investor Presentation & Financial Highlights. May 2018

Investor Presentation & Financial Highlights. May 2018 Investor Presentation & Financial Highlights May 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual

More information

Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO

Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE. January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO Abbott 36 TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE January 8, 2018 Brian Yoor, Executive Vice President, Finance and CFO FORWARD LOOKING STATEMENT Some statements in this presentation may be forward-looking

More information

Quarterly Update For the three months to 31 October 2017

Quarterly Update For the three months to 31 October 2017 Quarterly Update For the three months to 31 October 2017 Highlights Realisation activity key driver of growth in the quarter NAV per share of 930p Highly cash generative portfolio YTD distributions exceed

More information

Siegfried at a Glance. March 2018

Siegfried at a Glance. March 2018 Siegfried at a Glance March 2018 Who are we? Company founded 140 years ago Long-term tradition of pharmaceutics and chemicals Unique selling proposition (USP): development and manufacturing services of

More information

Do Mid-Cap Private Equity Funds Have an Advantage in Today s Markets?

Do Mid-Cap Private Equity Funds Have an Advantage in Today s Markets? Do Mid-Cap Private Equity Funds Have an Advantage in Today s Markets? Richard Cashin, Managing Partner, One Equity Partners Ellis Jones, CEO, Wasserstein & Co. John Mapes, Managing Partner, Aurora Capital

More information

Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile Bionure Farma SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile BioPortfolio has been marketing business and

More information

4 th Quarter Earnings Conference Call

4 th Quarter Earnings Conference Call 4 th Quarter Earnings Conference Call KKR & Co. L.P. Investor Update February 11, 2016 Gross Returns $1B+ Carry Paying Funds Q4 and 2015 Performance Market Indices Private Equity Real Assets Alternative

More information

Investor Presentation & Financial Highlights. November 2018

Investor Presentation & Financial Highlights. November 2018 Investor Presentation & Financial Highlights November 2018 Forward Looking Statements Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties.

More information

Opportunity in Small & Mid Cap

Opportunity in Small & Mid Cap Opportunity in Small & Mid Cap - A Private Equity Investing approach Presentation by Hiren Ved Alchemy Capital Management October 20 Presentation ti Path Investment Life Cycle Private equity opportunities

More information

2,500,000 Shares. Common Stock

2,500,000 Shares. Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-201841 Prospectus Supplement No. 15 to Prospectus dated February 26, 2015 2,500,000 Shares Common Stock This Prospectus Supplement No. 15

More information

Wineus AG. Company presentation 2016

Wineus AG. Company presentation 2016 Wineus AG Company presentation 2016 Wineus Entrepreneurial Finance Your success is our success Our customers Entrepreneurs Investors Public and private companies Our services Investment advisory Mergers

More information

Overview of Venture Equity

Overview of Venture Equity Overview of Venture Equity SVB Analytics Report 2017 Written by SVB Analytics: Steve Liu Managing Director sliu@svb.com Sean Lawson Senior Manager slawson2@svb.com Steven Pipp Senior Associate spipp@svb.com

More information

HBM Healthcare Investments Ltd

HBM Healthcare Investments Ltd HBM Healthcare Investments Ltd Access to a Global and Diversified Healthcare Portfolio November 2018 HBM Healthcare Investments Ltd About HBM Healthcare Investments Ltd Investment Strategy Healthcare Sector

More information

27 August 2015 SUBSEA JOINT VENTURE WITH CHIYODA CORPORATION

27 August 2015 SUBSEA JOINT VENTURE WITH CHIYODA CORPORATION 1794506-001 Central Equity_PPT Cover.pptx [ C L I E N T N A M E ] 27 August 2015 SUBSEA JOINT VENTURE WITH CHIYODA CORPORATION Important Notice This presentation is being issued by Ezra Holdings Limited

More information

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond

Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond Perspectives of Innovative Small Companies on the Industry s Prospects for 2012 and Beyond ACI Forum on Structuring, Negotiating and Managing Life Sciences Collaborations and Acquisitions February 28,

More information

ALANCO TECHNOLOGIES INC

ALANCO TECHNOLOGIES INC SECURITIES & EXCHANGE COMMISSION EDGAR FILING ALANCO TECHNOLOGIES INC Form: 8-K Date Filed: 2016-10-04 Corporate Issuer CIK: 98618 Copyright 2016, Issuer Direct Corporation. All Right Reserved. Distribution

More information

Shell s Journey to Mobility

Shell s Journey to Mobility Shell s Journey to Mobility Speakers: Yorinde Knegtering Business Analyst, IT Produce Hydrocarbons Prabhat Mishra Product Owner, PI Center of Excellence Definitions & cautionary note Reserves: Our use

More information

Venture Capital Report

Venture Capital Report Europe 4Q 2014 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs

More information

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan

New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan New Rhein concludes successful investment in Chase Pharmaceuticals via sale to Allergan NEWS PROVIDED BY New Rhein Healthcare Investors LLC Nov 22, 2016, 04:57 ET CHICAGO, Nov. 22, 2016 /PRNewswire/ --

More information

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast,

Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, Transparency Market Research Implantable Drug Delivery Devices Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 2018 Buy Now Request Sample Published Date: Mar 2013 Single User

More information

Halliburton and Baker Hughes Creating the leading oilfield services company

Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton and Baker Hughes Creating the leading oilfield services company Halliburton Investor Relations Contacts: Kelly Youngblood, Vice President Scott Danby, Manager 281.871.2688 or investors@halliburton.com

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 3Q 2015 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS

FUNDS DATABASE SCOPE INCLUSION CRITERIA DATA HIGHLIGHTS INDUSTRY RE FUNDS 1969 to present Industry surveys, quarterly and annual fund reports 9,240+ venture capital and private equity funds Venture capital and buyout funds that have invested in companies Name

More information

VENTURE CAPITAL. A Guide to Understanding Venture Capital

VENTURE CAPITAL. A Guide to Understanding Venture Capital VENTURE CAPITAL A Guide to Understanding Venture Capital This manual was created as resource guide for members of the Saskatchewan Trade and Export Partnership (STEP). For more information on these manuals

More information

Quarterly M&A Report Q3 2018

Quarterly M&A Report Q3 2018 John Hill hill@hydeparkcapital.com (813) 383-0205 John McDonald mcdonald@hydeparkcapital.com (813) 383-0206 Jeff Hendricks Vice President jhendricks@hydeparkcapital.com (678) 523 3073 Quarterly M&A Report

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K. ALCON INC. (Registrant Name)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 6-K. ALCON INC. (Registrant Name) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 2, 2019

More information

Acquisition of MST Medical Surgery Technologies Ltd:

Acquisition of MST Medical Surgery Technologies Ltd: Acquisition of MST Medical Surgery Technologies Ltd: Meaningfully Bolsters Senhance Platform Innovation to Further Advance Digital Laparoscopy September 24, 2018 2 FORWARD LOOKING STATEMENTS This presentation

More information

For personal use only

For personal use only ASX ANNOUNCEMENT AGM PRESENTATION SYDNEY, Monday 21 November 2016: Cellmid Limited (ASX:CDY) provides the following presentation for the Annual General Meeting of the shareholders. End Contact: Maria Halasz,

More information

Credit Suisse Energy Summit Transocean Ltd.

Credit Suisse Energy Summit Transocean Ltd. Credit Suisse Energy Summit Transocean Ltd. February 7, 2012 1 Legal Disclaimer The statements described in this presentation that are not historical facts are forward-looking statements within the meaning

More information

COURSE ON VENTURE CAPITAL AND ITS ROLE IN THE FUNDING OF START-UP COMPANIES

COURSE ON VENTURE CAPITAL AND ITS ROLE IN THE FUNDING OF START-UP COMPANIES CAPITAL PLUS PRIVATE LIMITED 10 ANSON ROAD #30-07 INTERNATIONAL PLAZA SINGAPORE 079903 PHONE 6559 9113 FAX 6250 0579 COURSE ON VENTURE CAPITAL AND ITS ROLE IN THE FUNDING OF START-UP COMPANIES Course Objective

More information

POWERING UP THE PITCH by Regina M Maxwell, MLIS, Maxwell Research Services LLC

POWERING UP THE PITCH by Regina M Maxwell, MLIS, Maxwell Research Services LLC WINTER 2015 TRACKING THE PULSE OF THE PHILADELPHIA LIFE SCIENCE INDUSTRY TABLE OF CONTENTS 1. POWERING UP THE PITCH by Regina M Maxwell, MLIS 2. GOT PATENTS? PRACTICAL CONSIDERATIONS FOR BIOTECH START-UPS

More information

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1%

Textron Reports Third Quarter 2014 Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% Textron Reports Third Quarter Income from Continuing Operations of $0.57 per Share, up 62.9%; Revenues up 18.1% 10/17/ PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported third

More information

Parametric Sound Corporation Investor Presentation May 2013

Parametric Sound Corporation Investor Presentation May 2013 Parametric Sound Corporation Investor Presentation May 2013 1 Safe Harbor Statement Other than statements of historical fact, all statements made in this presentation, are forward-looking statements within

More information

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE

Fall State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Fall 2015 State of the Industry Report UF SID MARTIN FLORIDA BIODATABASE Industry Overview The expansion of Florida s biotech industry remains resilient with an overall growth rate of 92% in the number

More information

All of the documents listed above are available on the Credit Suisse website.

All of the documents listed above are available on the Credit Suisse website. Annual Report 2018 Zurich, Credit Suisse Group AG and Credit Suisse AG, today, published the 2018 annual reporting suite, comprising the Annual Report, the Corporate Responsibility Report and the publication

More information

Trends in Healthcare Investments and Exits 2018

Trends in Healthcare Investments and Exits 2018 Trends in Healthcare Investments and Exits 208 208 Massachusetts Life Science Innovation Day Clark Hayes Managing Director Life Science/Healthcare Northeast Head of Business Development SVB Corporate Overview

More information

Private Equity and Venture Capital in Switzerland

Private Equity and Venture Capital in Switzerland Private Equity and Venture Capital in Switzerland Venture Valuation VV AG Badenerstr. 18 8004 Zurich Switzerland Phone +41 (43) 321 86 60 Fax + 41 (43) 321 86 61 info@venturevaluation.ch Agenda - Overview

More information

GLP CHINA LEADERSHIP TRANSITION

GLP CHINA LEADERSHIP TRANSITION For Immediate Release GLP CHINA LEADERSHIP TRANSITION Teresa Zhuge and Victor Mok promoted from within the China business to serve as Co-Presidents Dual leadership structure allows GLP to focus on strengthening

More information

Mining Indaba 2010 Russell Ball Executive Vice President & CFO February 2, 2010 Cape Town, South Africa

Mining Indaba 2010 Russell Ball Executive Vice President & CFO February 2, 2010 Cape Town, South Africa Mining Indaba 2010 Russell Ball Executive Vice President & CFO February 2, 2010 Cape Town, South Africa Newmont Mining Corporation February 2, 2010 Mining Indaba 1 Cautionary Statement This presentation

More information

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics

Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics 1 Financing Alternatives for Biotechnology Companies: A Case Study of Seattle Genetics Eric Dobmeier Chief Business Officer Life science startups are the only companies that are forced to define their

More information

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014

AMCo current. Medpace new in Sebia realised. Spire Healthcare partially realised. Healthcare. Sector insights. Our Healthcare portfolio in 2014 Sector insights The healthcare market is highly complex with global products delivered through local services and channels. The healthcare value chain is intricate, diverse and interdependent. It is a

More information

Venture Capital Report

Venture Capital Report Venture Capital Report Europe 3Q 2018 The following report presents Dow Jones VentureSource s quarterly findings for European venture capital fundraising, investment, valuation, and liquidity. The included

More information

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update

PwC Deals $42B. Global Pharma & Life Sciences Deals Insights Q Update PwC Deals Q3 16 Update Executive summary Global Pharma and Life Sciences (PLS) deal activity declined both in volume and value this quarter compared to the prior quarter and Q3 15. The considerable decrease

More information

$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance

$3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category. Deal at a Glance Reynolds American Enters Smokeless Tobacco Category Via Acquisition of Conwood $3.5 Billion Acquisition of Nation s No. 2 Company in Growing Moist Snuff Category Deal at a Glance 2005 Financial Summary

More information

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile

Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile Mesa Laboratories, Inc. (MLAB) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

Mara H. Rogers, Partner Norton Rose Fulbright

Mara H. Rogers, Partner Norton Rose Fulbright Mara H. Rogers Partner Norton Rose Fulbright US LLP New York T:+1 212 318 3206 F:+1 212 318 3400 mara.rogers@nortonrosefulbright.com vcard (+Outlook) Related services Corporate, M&A and securities Mergers

More information

Finomics Business Conclave of XIMB, XUB

Finomics Business Conclave of XIMB, XUB Finomics 2016 Business Conclave of XIMB, XUB THE CONCLAVE Startup Funding & Valuation Bubble Is it the Beginning or the End? DATE: 6 TH AUGUST, 2016 VENUE: XAVIER INSTITUTE OF MANAGEMENT, BHUBANESWAR 5

More information

Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD

Gilead Sciences. Very interesting in all areas. COMPANY Gilead Sciences Inc. INDUSTRY Biotechnology TYPE Public Company TICKER NasdaqGS:GILD Simply Wall St provides a completely new visual way to invest in the stock market. To see other infographic reports like this one for Apple check out simplywall.st. Very interesting in all areas. COMPANY

More information

Investor Presentation

Investor Presentation Investor Presentation Safe Harbor Statement Certain information set forth in this presentation contains forward-looking information, including future oriented financial information and financial outlook,

More information

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5%

Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% Textron Reports Second Quarter 2014 Income from Continuing Operations of $0.51 per Share, up 27.5%; Revenues up 23.5% 07/16/2014 PROVIDENCE, R.I.--(BUSINESS WIRE)-- Textron Inc. (NYSE: TXT) today reported

More information

AMERICAS SILVER CORPORATION PROVIDES FIRST QUARTER PRODUCTION AND COST UPDATE INCLUDING RECORD LOW CASH COSTS AND ALL IN SUSTAINING COSTS

AMERICAS SILVER CORPORATION PROVIDES FIRST QUARTER PRODUCTION AND COST UPDATE INCLUDING RECORD LOW CASH COSTS AND ALL IN SUSTAINING COSTS AMERICAS SILVER CORPORATION PROVIDES FIRST QUARTER PRODUCTION AND COST UPDATE INCLUDING RECORD LOW CASH COSTS AND ALL IN SUSTAINING COSTS TORONTO, ONTARIO April 7, 208 Americas Silver Corporation (TSX:

More information